MedTrace Logo

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-04-06

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Conditions

  • Metastatic Solid Tumor
  • Advanced Solid Tumor

Interventions

DRUG

CHS-114

Solution for infusion

DRUG

Toripalimab

Solution for infusion

DRUG

5 Fluorouracil

Solution for infusion

DRUG

Cisplatin

Solution for infusion

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06657144 on ClinicalTrials.gov